- Home
- NRT vs KLRS Comparison
NRT vs KLRS Comparison
Compare NRT & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- KLRS
- Stock Information
- Founded
- NRT 1975
- KLRS 2019
- Country
- NRT United States
- KLRS United States
- Employees
- NRT N/A
- KLRS N/A
- Industry
- NRT Oil & Gas Production
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRT Energy
- KLRS Health Care
- Exchange
- NRT Nasdaq
- KLRS Nasdaq
- Market Cap
- NRT 50.9M
- KLRS 46.0M
- IPO Year
- NRT N/A
- KLRS N/A
- Fundamental
- Price
- NRT $5.63
- KLRS $4.74
- Analyst Decision
- NRT
- KLRS Strong Buy
- Analyst Count
- NRT 0
- KLRS 2
- Target Price
- NRT N/A
- KLRS $23.00
- AVG Volume (30 Days)
- NRT 31.0K
- KLRS 175.7K
- Earning Date
- NRT 08-29-2025
- KLRS 11-15-2025
- Dividend Yield
- NRT 8.53%
- KLRS N/A
- EPS Growth
- NRT 24.05
- KLRS N/A
- EPS
- NRT 0.59
- KLRS N/A
- Revenue
- NRT $6,184,173.00
- KLRS N/A
- Revenue This Year
- NRT N/A
- KLRS N/A
- Revenue Next Year
- NRT N/A
- KLRS N/A
- P/E Ratio
- NRT $9.60
- KLRS N/A
- Revenue Growth
- NRT 18.55
- KLRS N/A
- 52 Week Low
- NRT $3.88
- KLRS $2.14
- 52 Week High
- NRT $5.87
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- NRT 56.50
- KLRS 47.23
- Support Level
- NRT $5.49
- KLRS $4.60
- Resistance Level
- NRT $5.71
- KLRS $5.30
- Average True Range (ATR)
- NRT 0.18
- KLRS 0.44
- MACD
- NRT 0.01
- KLRS -0.08
- Stochastic Oscillator
- NRT 80.00
- KLRS 45.63
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.